Axios

Novavax is seeking emergency authorization of its COVID-19 booster shot from the Food and Drug Administration, the company announced on Monday.

The big picture: The booster shot would be available to people who got two doses of the Novavax vaccines, as well as to those who got another vaccine.

Less than a third of the 63 National Cancer Institute-designated cancer centers in the U.S. are fully complying with federal price transparency rules, according to an analysis in JAMA Surgery.

Why it matters: Cancer treatment can be particularly costly, leading some patients to face crippling debt and even bankruptcy in their bid to find a cure.

Regulators in the United Kingdom on Monday approved a COVID-19 booster for adults that targets both the original virus and the Omicron variant.

Why it matters: Monday's approval makes the United Kingdom the first in the world to authorize the bivalent COVID-19 booster, the updated version of Moderna’s vaccine.

After Twitter began offering further monkeypox information to users, GLAAD is putting out a call for other social media platforms to follow suit.

Why it matters: As monkeypox has spread in the U.S., so has online misinformation about how it is contracted and who is at risk.

Democrats are on the cusp of their most significant health policy victory since passage of the Affordable Care Act, but the legislative wrangling it took to get here came at a steep cost: The prescription drug pricing reforms included in the health, tax and climate package are limited to Medicare and exclude the millions of Americans with private insurance.

Why it matters: At best, this sets up a two-tiered pricing system for certain drugs, in which employers and enrollees in the commercial market will pay a significantly higher rate than the government in the years to come. And at worst, some employers and experts warn, it could cause drug prices to actually rise in the private market.